News|Articles|October 9, 2025
Streamline AAV-based Gene Therapies with High-Performing Off-the-Shelf Plasmids
Author(s)Catalent
Key Takeaways
Optimized plasmids are vital for viral vector production. Catalent’s off-the-shelf plasmids help AAV gene therapy developers enhance efficiency, reduce costs, and improve consistency across development and manufacturing.
Newsletter
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.
Related Content
Trending on BioPharm International
1
Launch in Lockstep: Biopharma Readiness for the CNPV’s Accelerated Clock
2
How Miniaturized Analytics Are Transforming Aseptic Bioprocessing Control
3
How Programmable Biology Could Reshape Biologic Drug Development
4
Industry Experts Probe CNPV Impacts
5
